Showing results (1211-1220 of 1,246) with videos related to

Sort By:
Pageof 125
Nature Medicine|September 28, 2018
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individualsYotam Bar-On, Henning Gruell, Till Schoofs, et al.
Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)Stephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
Life (Basel, Switzerland)|July 2, 2021
Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing CountriesBrian Godman, Abiodun Egwuenu, Mainul Haque, et al.
Health Technology Assessment (Winchester, England)|August 3, 2019
Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCTMatthew Scarborough, Ho Kwong Li, Ines Rombach, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapyMohammed Altaf, Carla Nel, Timothy Tipoe, et al.
BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
BMC Infectious Diseases|March 27, 2019
Ten years of external quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in Europe elucidate high reliability of dataMichelle J Cole, Nerteley Quaye, Susanne Jacobsson, et al.
Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.
Pageof 125